gdme0833cdb - becton, dickinson and company market share ... · becton, dickinson and company...

Becton, Dickinson and Company Market Share Analysis GDME0833CDB / Published April 2013

© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form

Becton, Dickinson and Company Market Share Analysis

Reference Code: GDME0833CDB Publication Date: April 2013

Table of Contents



1 Table of Contents

1 Table of Contents ................................................................................................................ 2

1.1 List of Tables ....................................................................................................................................................... 16

1.2 List of Figures ..................................................................................................................................................... 19

2 Introduction ....................................................................................................................... 22

2.1 What Is This Report About? .............................................................................................................................. 22

3 Definitions of Markets/Categories Covered .................................................................... 23

3.1 In Vitro Diagnostics ............................................................................................................................................ 23 3.1.1 Histology And Cytology ................................................................................................................................. 23 3.1.2 Infectious Immunology .................................................................................................................................. 23 3.1.3 Microbiology Culture ..................................................................................................................................... 23

3.2 Hospital Supplies ................................................................................................................................................ 23 3.2.1 Disposable Hospital Supplies ....................................................................................................................... 23 3.2.2 Syringes and Needles ................................................................................................................................... 23

3.3 Drug Delivery Devices ....................................................................................................................................... 23 3.3.1 Central Venous Catheters ............................................................................................................................ 24

3.4 Diabetes Care Devices ....................................................................................................................................... 24 3.4.1 Insulin Delivery .............................................................................................................................................. 24

3.5 Anesthesia and Respiratory Devices .............................................................................................................. 24 3.5.1 Regional Anesthesia Disposables ............................................................................................................... 24

4 Company Snapshot .......................................................................................................... 25

4.1 Key Facts.............................................................................................................................................................. 25

4.2 Company Overview ............................................................................................................................................ 25

4.3 Financial Performance ....................................................................................................................................... 25

4.4 SWOT Snapshot .................................................................................................................................................. 25

5 Business Description ....................................................................................................... 26

Table of Contents



5.1 Business Overview ............................................................................................................................................. 26

5.2 Biosciences ......................................................................................................................................................... 26 5.2.1 Overview ........................................................................................................................................................ 26 5.2.2 Financials ....................................................................................................................................................... 26 5.2.3 Capital Expenditure ....................................................................................................................................... 26

5.3 Diagnostics .......................................................................................................................................................... 27 5.3.1 Overview ........................................................................................................................................................ 27 5.3.2 Financials ....................................................................................................................................................... 27 5.3.3 Capital Expenditure ....................................................................................................................................... 27

5.4 Medical.................................................................................................................................................................. 27 5.4.1 Overview ........................................................................................................................................................ 27 5.4.2 Financials ....................................................................................................................................................... 27 5.4.3 Capital Expenditure ....................................................................................................................................... 27

5.5 Major Products and Services ........................................................................................................................... 28 5.5.1 Overview ........................................................................................................................................................ 28

6 History ............................................................................................................................... 40

7 Business Strategy ............................................................................................................. 47

7.1 Mission Statement .............................................................................................................................................. 47

8 SWOT Analysis ................................................................................................................. 48

8.1 Overview ............................................................................................................................................................... 48

8.2 Becton, Dickinson and Company Strengths .................................................................................................. 48 8.2.1 Improving Liquidity Reserves ....................................................................................................................... 48 8.2.2 Focused Research and Development Efforts ............................................................................................. 49 8.2.3 Geographical Diversity .................................................................................................................................. 49 8.2.4 Diverse Product Portfolio .............................................................................................................................. 49

8.3 Becton, Dickinson and Company Weaknesses............................................................................................. 49 8.3.1 Product Recalls ............................................................................................................................................. 49 8.3.2 Pending Lawsuits .......................................................................................................................................... 50

8.4 Becton, Dickinson and Company Opportunities .......................................................................................... 51 8.4.1 Strategic Acquisitions .................................................................................................................................... 51 8.4.2 Growing Diabetes Care Devices Market ..................................................................................................... 51 8.4.3 Agreements and Collaborations ................................................................................................................... 51 8.4.4 Market Growth in Emerging Economies ...................................................................................................... 51

Table of Contents



8.5 Becton, Dickinson and Company Threats...................................................................................................... 52 8.5.1 Stringent Regulations .................................................................................................................................... 52 8.5.2 Competitive Environment .............................................................................................................................. 52 8.5.3 Government Funding Risks .......................................................................................................................... 53 8.5.4 Industry Consolidation Challenges .............................................................................................................. 53

9 Competitors ....................................................................................................................... 54

10 Competitive Landscape ................................................................................................. 56

10.1 In Vitro Diagnostics (Histology And Cytology), Global, Company Share (%), 2011 ............................... 56

10.2 Becton, Dickinson and Company, In Vitro Diagnostics (Histology And Cytology), by Region, Company Share (%) , 2011 ........................................................................................................................................... 58

10.3 Becton, Dickinson and Company, In Vitro Diagnostics (Histology And Cytology), by Country, Company Share (%) ,2011............................................................................................................................................. 59

10.4 In Vitro Diagnostics (Infectious Immunology), Global, Company Share (%), 2011................................. 61

10.5 Becton, Dickinson and Company, In Vitro Diagnostics (Infectious Immunology), by Region, Company Share (%) , 2011 ........................................................................................................................................... 63

10.6 Becton, Dickinson and Company, In Vitro Diagnostics (Infectious Immunology), by Country, Company Share (%) , 2011 ........................................................................................................................................... 65

10.7 In Vitro Diagnostics (Microbiology Culture), Global, Company Share (%), 2011 .................................... 67

10.8 Becton, Dickinson and Company, In Vitro Diagnostics (Microbiology Culture), by Region, Company Share (%), 2011 ............................................................................................................................................................... 69

10.9 Becton, Dickinson and Company, In Vitro Diagnostics (Microbiology Culture), by Country, Company Share (%) , 2011 .............................................................................................................................................................. 70

10.10 Hospital Supplies (Disposable Hospital Supplies), Global, Company Share (%), 2011 ..................... 72

10.11 Becton, Dickinson and Company, Hospital Supplies (Disposable Hospital Supplies), by Region, Company Share (%) , 2011 ........................................................................................................................................... 74

10.12 Becton, Dickinson and Company, Hospital Supplies (Disposable Hospital Supplies), by Country, Company Share (%) , 2011 ........................................................................................................................................... 75

10.13 Hospital Supplies (Syringes and Needles), Global, Company Share (%), 2011 ................................... 77

10.14 Becton, Dickinson and Company, Hospital Supplies (Syringes and Needles), by Region, Company Share (%) , 2011 .............................................................................................................................................................. 79

Table of Contents



10.15 Becton, Dickinson and Company, Hospital Supplies (Syringes and Needles), by Country, Company Share (%) , 2011 ........................................................................................................................................... 81

10.16 Drug Delivery Devices (Central Venous Catheters), Global, Company Share (%), 2011 ................... 83

10.17 Becton, Dickinson and Company, Drug Delivery Devices (Central Venous Catheters), by Region, Company Share (%) , 2011 ........................................................................................................................................... 85

10.18 Becton, Dickinson and Company, Drug Delivery Devices (Central Venous Catheters), by Country, Company Share (%) , 2011 ........................................................................................................................................... 86

10.19 Diabetes Care Devices (Insulin Delivery), Global, Company Share (%), 2011 ..................................... 88

10.20 Becton, Dickinson and Company, Diabetes Care Devices (Insulin Delivery), by Region, Company Share (%) , 2011 .............................................................................................................................................................. 90

10.21 Becton, Dickinson and Company, Diabetes Care Devices (Insulin Delivery), by Country, Company Share (%) , 2011 .............................................................................................................................................................. 91

10.22 Anesthesia and Respiratory Devices (Regional Anesthesia Disposables), Global, Company Share (%), 2011 .......................................................................................................................................................................... 93

10.23 Becton, Dickinson and Company, Anesthesia and Respiratory Devices (Regional Anesthesia Disposables), by Region, Company Share (%) , 2011 ............................................................................................. 95

10.24 Becton, Dickinson and Company, Anesthesia and Respiratory Devices (Regional Anesthesia Disposables), by Country, Company Share (%) , 2011 ............................................................................................ 97

11 Becton, Dickinson and Company Medical Equipment Company Share Analysis by Category .................................................................................................................................. 99

11.1 Becton, Dickinson and Company, Global, Category Revenue Share (2011) ........................................... 99

11.2 Becton, Dickinson and Company, Asia-Pacific, Category Revenue Share (2011) ................................ 102 11.2.1 Becton, Dickinson and Company, Australia, Category Revenue Share (2011) ..................................... 105 11.2.2 Becton, Dickinson and Company, China, Category Revenue Share (2011) .......................................... 108 11.2.3 Becton, Dickinson and Company, India, Category Revenue Share (2011) ............................................ 111 11.2.4 Becton, Dickinson and Company, Japan, Category Revenue Share (2011) .......................................... 114 11.2.5 Becton, Dickinson and Company, Other Asia-Pacific, Category Revenue Share (2011) ...................... 117

11.3 Becton, Dickinson and Company, Europe, Category Revenue Share (2011) ........................................ 120 11.3.1 Becton, Dickinson and Company, France, Category Revenue Share (2011) ........................................ 123 11.3.2 Becton, Dickinson and Company, Germany, Category Revenue Share (2011) .................................... 126 11.3.3 Becton, Dickinson and Company, Italy, Category Revenue Share (2011) ............................................. 129 11.3.4 Becton, Dickinson and Company, Spain, Category Revenue Share (2011) .......................................... 132 11.3.5 Becton, Dickinson and Company, United Kingdom, Category Revenue Share (2011) ......................... 135

Table of Contents



11.3.6 Becton, Dickinson and Company, Other Europe, Category Revenue Share (2011) ............................. 138

11.4 Becton, Dickinson and Company, Middle East and Africa, Category Revenue Share (2011) ............. 141

11.5 Becton, Dickinson and Company, North America, Category Revenue Share (2011) ........................... 144 11.5.1 Becton, Dickinson and Company, Canada, Category Revenue Share (2011) ....................................... 147 11.5.2 Becton, Dickinson and Company, United States, Category Revenue Share (2011) ............................. 150

11.6 Becton, Dickinson and Company, South and Central America, Category Revenue Share (2011) ..... 153 11.6.1 Becton, Dickinson and Company, Brazil, Category Revenue Share (2011)........................................... 156 11.6.2 Becton, Dickinson and Company, Other South and Central America, Category Revenue Share (2011) 159

12 Share Holding Structure .............................................................................................. 162

13 Key Employees ............................................................................................................ 163

14 Key Employee Biographies ......................................................................................... 164

15 Company Statement .................................................................................................... 165

16 Locations And Subsidiaries ........................................................................................ 167

16.1 Head Office ........................................................................................................................................................ 167

16.2 Other Locations & Subsidiaries ..................................................................................................................... 167

17 Financial Deals Landscape ......................................................................................... 172

17.1 Becton, Dickinson and Company, Deals Volume Summary, 2007 to 2012 ............................................ 172

18 Becton, Dickinson and Company, Deals Summary By Region, 2007 to 2012 ........ 173

19 Becton, Dickinson and Company Detailed Deal Summary ...................................... 175

19.1 Asset Purchase ................................................................................................................................................. 175 19.1.1 BD Diagnostics Completes Acquisition Of Lab Systems Division From Dynacon ................................. 175

19.2 Venture Financing ............................................................................................................................................ 176 19.2.1 Sirigen Secures $3 Million In Venture Financing ...................................................................................... 176 19.2.2 Sirigen Secures $6.13 Million In Venture Financing ................................................................................. 178 19.2.3 Accuri Cytometers Secures $6 Million In Series E Preferred Stock Financing Round .......................... 180 19.2.4 Accuri Cytometers Secures $4 Million In Series D Round Of Financing ................................................ 182 19.2.5 Sirigen Secures Additional $1.96 Million In Financing ............................................................................. 184

Table of Contents



19.2.6 Pathogenetix Secures $4.5 Million In Venture Financing ......................................................................... 186 19.2.7 Accuri Cytometers Secures $13 Million In Series C Financing................................................................ 187 19.2.8 Sirigen Secures $3.96 Million In Financing ............................................................................................... 189 19.2.9 Accuri Cytometers Raises $5 Million In Series B Financing .................................................................... 190

19.3 Private Equity .................................................................................................................................................... 191 19.3.1 Becton, Dickinson and Company Completes Sale Of Ophthalmic Systems Unit To RoundTable Healthcare Partners ................................................................................................................................................... 191

19.4 Partnerships ...................................................................................................................................................... 193 19.4.1 Asuragen Enters Into Licensing Agreement With Becton, Dickinson ...................................................... 193 19.4.2 SDIX Enters Into Licensing Agreement With BD Diagnostic ................................................................... 194 19.4.3 Acacia Research Enters Into Licensing Agreement With Becton, Dickinson And Argon Medical ........ 195 19.4.4 Becton, Dickinson Enters Into Licensing Agreement With Advanced Analytical Technologies For Micro PRO Microbial Detection System .............................................................................................................................. 196 19.4.5 UCL Business Enters Into Licensing Agreement With Becton, Dickinson .............................................. 197 19.4.6 Exiqon Enters Into Licensing Agreement With Becton, Dickinson .......................................................... 198 19.4.7 Caliper Life Sciences Enters Into Licensing Agreement With Becton, Dickinson and Company .......... 199 19.4.8 Arbor Vita Signs An Agreement With Becton, Dickinson and Company ................................................. 200 19.4.9 Ivera Medical Enters Into An Agreement With Becton, Dickinson and Company .................................. 201 19.4.10 Proteome Systems Enters Into Licensing Agreement With Becton, Dickinson and Company ......... 202 19.4.11 BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays .... 203 19.4.12 Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test ... 204 19.4.13 Juvenile Diabetes Research Foundation Extends Co-Development Agreement With Becton, Dickinson 205 19.4.14 BD Diagnostics Enters Into Co-Development Agreement With Biodiversity ....................................... 206 19.4.15 BD Diagnostics Enters Into Co-Development Agreement With Lab21................................................ 207 19.4.16 BD Diagnostic Enters Into Co-Development Agreement With Diagenode .......................................... 208 19.4.17 BD Diagnostic Enters Into An Agreement With Bruker Daltonics ........................................................ 209 19.4.18 Alverix Enters Into Co-Development Agreement With Becton, Dickinson .......................................... 210 19.4.19 JDRF Enters Into An Agreement With Becton, Dickinson and Company ........................................... 211 19.4.20 BD Diagnostics Enters Into An Agreement With HandyLab................................................................. 212 19.4.21 Becton, Dickinson and Company Signs An Agreement With Fujirebio Diagnostics .......................... 213 19.4.22 LiDCO Group Extends Co-Marketing Agreement With Becton, Dickinson and Company ................ 214 19.4.23 LiDCO Group Enters Into Distribution Agreement With Becton, Dickinson and Company ................ 215 19.4.24 HyperBranch Medical Technology Enters Into An Agreement With BD .............................................. 216 19.4.25 Luminex Enters Into An Agreement With BD Diagnostics-TriPath ...................................................... 217 19.4.26 U.S. Genomics Enters Into Co-Development Agreement With Becton, Dickinson and Company .... 218 19.4.27 Accelr8 Technology Enters Into Co-Development Agreement With Becton, Dickinson and Company 219 19.4.28 Proteome Systems Enters Into Agreement With Becton, Dickinson ................................................... 220 19.4.29 BD Diagnostic Systems Enters Into Licensing Agreement With Lonza Group ................................... 221 19.4.30 Centenary Institute of Cancer Medicine and Cell Biology And Bio-Link Enter Into Licensing Agreement With Becton, Dickinson and Company .................................................................................................. 222

Table of Contents



19.5 Equity Offering .................................................................................................................................................. 223 19.5.1 Becton, Dickinson Files Registration Statement For Public Offering Of Securities ................................ 223 19.5.2 Becton, Dickinson Completes Public Offering Of Notes Due 2021 For $1 Billion .................................. 224 19.5.3 Becton, Dickinson Completes Public Offering Of Notes Due 2016 For $500 Million ............................. 225 19.5.4 Becton, Dickinson and Company Completes Underwritten Public Offering Of Senior Unsecured Notes Due 2040 For $300 Million......................................................................................................................................... 226 19.5.5 Becton, Dickinson Completes Underwritten Public Offering Of Senior Unsecured Notes Due 2020 For $700 Million ................................................................................................................................................................. 227 19.5.6 Becton, Dickinson and Company Completes Public Offering Of 6% Notes For $250 Million ............... 228 19.5.7 Becton, Dickinson and Company Completes Public Offering Of 5% Notes For $500 Million ............... 230

19.6 Asset Transactions........................................................................................................................................... 232 19.6.1 Corning Completes Acquisition of Majority Stake In Discovery Labware Unit Of Becton, Dickinson For $730 Million ................................................................................................................................................................. 232 19.6.2 Becton, Dickinson and Company Completes Sale Of Assets To Argon Medical Devices .................... 234 19.6.3 Becton, Dickinson and Company Completes Sale Of Assets To Aspen Surgical Products .................. 235 19.6.4 3M Acquires ACE Branded Bandage And Thermometer Product Line From BD .................................. 236

19.7 Acquisition ......................................................................................................................................................... 237 19.7.1 Becton, Dickinson Acquires Cato Software Solutions, Maker Of Medical Software Solutions .............. 237 19.7.2 Becton, Dickinson Completes Acquisition Of Safety Syringes, Developer Of Anti-Needlestick Devices 238 19.7.3 Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes .......................................................... 239 19.7.4 Becton, Dickinson Acquires KIESTRA, Provider Of Lab Automation Solutions ..................................... 241 19.7.5 Becton, Dickinson Completes Acquisition Of Carmel Pharma ................................................................ 242 19.7.6 Becton, Dickinson Completes Acquisition Of Accuri Cytometers ............................................................ 244 19.7.7 Becton, Dickinson and Company Completes Acquisition Of HandyLab ................................................. 246 19.7.8 Priveq Acquires 25.9% Stake In Carmel Pharma From 3i ....................................................................... 247

20 Recent Developments ................................................................................................. 249

20.1 Strategy And Business Planning ................................................................................................................... 249 20.1.1 May 02, 2012: BD Opens Major Distribution Center In Four Oaks, North Carolina ............................... 249 20.1.2 Mar 27, 2012: BD And FIND Extend Pricing Agreement To Reach HIV-Positive Patients In India ...... 249 20.1.3 Feb 14, 2012: BD And PEPFAR Launch Center For Excellence In Phlebotomy And Specimen Collection At KMTC .................................................................................................................................................... 250 20.1.4 Jan 19, 2012: BD And Mercy/ROi Collaborate To Improve Quality Of Care And Reduce Costs ......... 251 20.1.5 Apr 13, 2011: BD And Waste Management Healthcare Solutions Launch Initiative To Recycle Medical Sharps 252 20.1.6 Jan 24, 2011: BD And Rady Children's Hospital-San Diego Announce New Pilot Project To Reduce Environmental Impact Of Sharps Disposal ............................................................................................................... 252 20.1.7 Oct 01, 2010: BD Commences Construction Of Warehouse And East Coast Distribution Center In Johnston County......................................................................................................................................................... 253 20.1.8 Apr 08, 2010: BD Opens New Manufacturing Facility In Tatabanya, Hungary ....................................... 253

Table of Contents



20.1.9 Mar 01, 2010: BD Opens New Manufacturing Facility In San Luis Potosi, Mexico ................................ 253 20.1.10 Nov 20, 2009: BD Acquires HandyLab .................................................................................................. 254 20.1.11 Oct 27, 2009: BD To Launch Operations At Its EUR100 Million Plant In Hungary ............................ 254 20.1.12 Jun 09, 2009: BD Buys New Facility In Mebane To Employ More Workers ....................................... 254 20.1.13 May 04, 2009: BD And Fujirebio Sign Worldwide Agreement To Develop Biomarker Assays To Improve Cancer Detection And Management .......................................................................................................... 255 20.1.14 Sep 18, 2008: Oxonica Signs Strategic Agreement With Becton, Dickinson For Nanoplex Technology 255 20.1.15 Sep 10, 2008: BD Opens New Automated Warehouse In Fraga ........................................................ 256 20.1.16 Jun 10, 2008: BD Opens New Manufacturing Center In Quebec, Canada ......................................... 256 20.1.17 Mar 14, 2008: BD Expands Operations In US....................................................................................... 256

20.2 Financial Announcements .............................................................................................................................. 257 20.2.1 Feb 05, 2013: BD Reports Revenue Of $1.9 Billion In Q1 Fiscal 2013 .................................................. 257 20.2.2 Nov 07, 2012: BD Reports Revenue Of $7.7 Billion In Fiscal 2012 ........................................................ 258 20.2.3 Aug 02, 2012: BD Reports Revenue Of $2 Billion In Q3 Fiscal 2012 ..................................................... 259 20.2.4 May 01, 2012: BD Reports Revenue Of $2 Billion In Q2 Fiscal 2012 ..................................................... 260 20.2.5 Feb 07, 2012: BD Reports Revenue Of $1.9 Billion In Q1 Fiscal 2012 .................................................. 261 20.2.6 Nov 02, 2011: BD Reports Revenue Of $7.8 Billion In Fiscal Year Ended 2011 ................................... 262 20.2.7 Aug 02, 2011: BD Reports Revenues Of $2 Billion In Q3 Fiscal Year Ended 2011 .............................. 263 20.2.8 Apr 26, 2011: BD Reports Revenues Of $1.9 Billion In Q2 Fiscal Year Ended 2011 ............................ 265 20.2.9 Feb 07, 2011: BD Reports Net Income Of $315.94 Million In Q1 Fiscal 2011 ....................................... 266 20.2.10 Nov 03, 2010: BD Reports Net Income Of $1.32 Billion In Fiscal 2010 .............................................. 267 20.2.11 Jul 29, 2010: BD Reports Net Income Of $306.91 Million In Q3 Fiscal 2010 ..................................... 267 20.2.12 Apr 30, 2010: BD Reports Net Income Of $297.6 Million In Q2 Fiscal 2010 ...................................... 268 20.2.13 Jan 28, 2010: BD Reports Net Income Of $316.4 Million In Q1 Fiscal 2010 ...................................... 269 20.2.14 Nov 04, 2009: BD Reports Net Income Of $1.23 Billion In Fiscal 2009 .............................................. 270 20.2.15 Jul 30, 2009: BD Reports Net Income Of $341 Million In Q3 Fiscal 2009 .......................................... 271 20.2.16 Apr 28, 2009: BD Reports Net Income Of $261.3 Million In Q2 Fiscal 2009 ...................................... 272 20.2.17 Feb 03, 2009: BD Declares Quarterly Dividend .................................................................................... 273 20.2.18 Jan 28, 2009: BD Reports Q1 Fiscal 2009 Results .............................................................................. 273 20.2.19 Nov 25, 2008: BD Declares Quarterly Dividend .................................................................................... 274 20.2.20 Nov 05, 2008: BD Reports Fiscal 2008 Results .................................................................................... 274 20.2.21 Jul 24, 2008: BD Reports 3Q Fiscal 2008 Results................................................................................ 276 20.2.22 Jul 22, 2008: BD Declares Quarterly Dividend ...................................................................................... 277 20.2.23 May 20, 2008: BD Declares Quarterly Dividend ................................................................................... 277 20.2.24 Apr 23, 2008: BD Reports Q2 Fiscal 2008 Results............................................................................... 277 20.2.25 Mar 18, 2008: BD Elects New Vice Chairman, CFO ............................................................................ 278 20.2.26 Jan 29, 2008: BD Declares Quarterly Dividend .................................................................................... 279 20.2.27 Jan 24, 2008: BD Reports Q1 Fiscal 2008 Results .............................................................................. 279 20.2.28 Nov 20, 2007: BD Declares Quarterly Dividend .................................................................................... 280 20.2.29 Nov 01, 2007: BD Reports Q4 Fiscal 2007 Results .............................................................................. 280 20.2.30 Jul 26, 2007: BD Reports Q3 Fiscal 2007 Results................................................................................ 281 20.2.31 Jul 24, 2007: BD Declares Quarterly Dividend ...................................................................................... 282

Table of Contents



20.2.32 Jul 24, 2007: BD Announces Share Repurchase Program .................................................................. 282 20.2.33 May 22, 2007: BD Declares Quarterly Dividend ................................................................................... 282 20.2.34 Apr 25, 2007: BD Reports Q2 Fiscal 2007 Results............................................................................... 282 20.2.35 Jan 30, 2007: BD Declares Quarterly Dividend .................................................................................... 283 20.2.36 Jan 25, 2007: BD Reports Q1 Fiscal 2007 Results .............................................................................. 284

20.3 Research And Development ........................................................................................................................... 285 20.3.1 Oct 15, 2009: Tyrian Seeks New Partner Opportunities For Tuberculosis Diagnostic Tests ................ 285

20.4 Corporate Communications............................................................................................................................ 286 20.4.1 Mar 13, 2013: BD Names Ellen Strahlman As CMO ................................................................................ 286 20.4.2 Nov 05, 2012: BD Appoints William A Kozy As COO ............................................................................... 286 20.4.3 Oct 10, 2012: BD Announces CFO Transition .......................................................................................... 287 20.4.4 Jul 23, 2012: BD Elects Rebecca W Rimel To Board............................................................................... 287 20.4.5 May 22, 2012: BD Appoints CEO Vincent A Forlenza As Chairman....................................................... 288 20.4.6 Jul 26, 2011: BD Appoints Vincent Forlenza As New CEO ..................................................................... 288 20.4.7 Jul 06, 2011: BD Diagnostics Appoints Patrick R Murray As Worldwide Director, Scientific Affairs, Diagnostic Systems .................................................................................................................................................... 289 20.4.8 Nov 16, 2010: BD Appoints Kathy Warye As Vice President, Infection Prevention ............................... 289 20.4.9 Jul 29, 2010: BD Announces Promotion Of President Vincent Forlenza ................................................ 290 20.4.10 Jul 26, 2010: BD Elects Christopher Jones To Board .......................................................................... 290 20.4.11 Mar 15, 2010: BD To Present At Barclays Capital 2010 Healthcare Conference .............................. 291 20.4.12 Sep 02, 2009: BD To Lay Off 22 People From Its Drogheda Production Plant, Ireland .................... 291 20.4.13 Mar 11, 2009: BD Biosciences Facility In San Jose, California Achieves LEED Silver Certification 291 20.4.14 Nov 05, 2008: BD Announces Management Appointments ................................................................. 292 20.4.15 Mar 18, 2008: BD Elects Vice Chairman And Board Member ............................................................. 293 20.4.16 Nov 02, 2007: BD Elects New Board Member ...................................................................................... 293 20.4.17 Jul 24, 2007: BD Elects New Director .................................................................................................... 293

20.5 Legal and Regulatory ....................................................................................................................................... 294 20.5.1 Oct 31, 2012: FTC Puts Conditions On Corning's Proposed Purchase Of Discovery Labware............ 294 20.5.2 Oct 04, 2012: Hologic Announces Favorable Ruling In Litigation With Becton, Dickinson ................... 295 20.5.3 Jul 11, 2011: Retractable Technologies Announces Decision From United States Court of Appeals for the Federal Circuit ...................................................................................................................................................... 295 20.5.4 Dec 20, 2010: BD Diagnostics Facility In Mebane, North Carolina Achieves LEED Silver Certification For Green Building Design ........................................................................................................................................ 296 20.5.5 Oct 04, 2010: Guide Flow Sues Six Companies Over Catheter Patent .................................................. 296 20.5.6 Jul 30, 2010: Federal Appeals Court Rules In Favor Of Covidien In Needle Patents Suit .................... 296 20.5.7 May 24, 2010: Retractable Reports Final Judgment And Permanent Injunction In Patent Litigation Suit Against BD .................................................................................................................................................................. 297 20.5.8 Nov 10, 2009: Retractable Announces Verdict In Patent Infringement Suit Against BD ....................... 297 20.5.9 Oct 21, 2009: Gen-Probe Files Patent Lawsuit Against BD ..................................................................... 297 20.5.10 Jul 27, 2009: BD India Files Lawsuit On Indian Health Ministry For Revoking Tender ...................... 298 20.5.11 Jan 07, 2009: BD Settles Lawsuit With Ultimed .................................................................................... 298

Table of Contents



20.6 Government and Public Interest .................................................................................................................... 299 20.6.1 Mar 07, 2012: Study Shows Nurses Are Exposed To Risks From Blood Exposure During Insertion And Removal Of Peripheral IV Catheter: BD ................................................................................................................... 299 20.6.2 Jul 29, 2010: FDA Requires Nine Companies To Conduct Postmarket Surveillance Study On Needleless Connectors .............................................................................................................................................. 300 20.6.3 Feb 26, 2009: Medical Equipments Manufacturers Oppose Easier Lawsuits ........................................ 300 20.6.4 Feb 25, 2009: Medical-Device Companies Supportive Of Comparative-Effectiveness Research ........ 301

20.7 Product News .................................................................................................................................................... 302 20.7.1 Apr 09, 2013: BD Receives FDA Approval For Max Cdiff Assay ............................................................ 302 20.7.2 Feb 28, 2013: BD’s Blood Culture Product Provides Statistically Significant Differences In Bacterial Recovery For Patients On Antimicrobial Therapy .................................................................................................... 302 20.7.3 Oct 11, 2012: BD Veritor System For Rapid Detection Of RSV Receives FDA 510(k) Clearance For Nasopharyngeal Wash, Aspirate And Swab In Transport Media Specimens ........................................................ 303 20.7.4 Oct 03, 2012: BD Diagnostics Receives 510(k) FDA Clearance For Nasopharyngeal Wash, Aspirate And Swab In Transport Media Specimens On BD Veritor System For Rapid Detection Of RSV ........................ 304 20.7.5 Sep 24, 2012: BD Diagnostics Receives FDA 510(k) Clearance For Nasopharyngeal Wash, Aspirate And Swab In Transport Media Specimens On BD Veritor System For Rapid Detection Of Flu A + B ................ 305 20.7.6 Aug 14, 2012: BD Diagnostics Receives CLIA Moderate Complexity Status For BD MAX MRSA Assay 306 20.7.7 Mar 31, 2012: BD MAX Cdiff Test Launches In Europe, Expanding HAI Portfolio On BD MAX System 307 20.7.8 Feb 08, 2012: Alverix’s Partner BD Receives Japanese Regulatory Approval For BD Veritor System For Flu A+B ................................................................................................................................................................. 307 20.7.9 Dec 20, 2011: Alverix Partner BD Receives 510(k) Clearance And CLIA Waiver For BD Veritor System For Rapid Detection Of Flu A+B ................................................................................................................................ 308 20.7.10 Nov 24, 2011: BD Diagnostics Receives CE Mark For BD MAX MRSA Assay ................................. 308 20.7.11 Oct 31, 2011: BD Introduces AutoShield Pen Needle In US ................................................................ 309 20.7.12 Sep 21, 2011: BD Launches New Generation BD Insyte Autoguard BC With Blood Control Technology ................................................................................................................................................................. 310 20.7.13 May 19, 2011: BD Diagnostics Launches BD MAX System In US ...................................................... 310 20.7.14 May 06, 2011: BD Launches BD Max Open System In Europe .......................................................... 311 20.7.15 Apr 04, 2011: New CDC Guidelines Recognize Value Of Split Septum IV Access Technology To Reduce Intravascular Catheter-Related Bloodstream Infections ............................................................................ 311 20.7.16 Jan 03, 2011: BD Diagnostics Files FDA 510(k) Clearance For HSV-1 And HSV-2 Qx Amplified DNA Assays 312 20.7.17 Oct 25, 2010: BD Announces BD Vacutainer Rapid Serum Tube Helps Improve Healthcare Worker Safety, Patient Care And Hospital Productivity ........................................................................................................ 312 20.7.18 Jun 17, 2010: BD Diagnostics Launches BD BACTEC MGIT 320 Mycobacteria Culture System.... 312 20.7.19 Jun 07, 2010: BD Launches BD Ultra-Fine Nano Pen Needle ............................................................ 313 20.7.20 Jun 02, 2010: BD Diagnostics Receives FDA 510(k) Approval For BD MAX GBS Assay For Group B Streptococcus ............................................................................................................................................................. 313 20.7.21 Jun 01, 2010: BD Diagnostics Announces US Launch Of BD Vacutainer Push Button Blood Collection Set With Pre-Attached Holder .................................................................................................................. 314

Table of Contents



20.7.22 Apr 06, 2010: BD Launches Innova Preanalytical Automated Microbiology Specimen Processor ... 314 20.7.23 Feb 08, 2010: BD Launches BD Microtainer MAP Microtube For Automated Process For Hematology Testing 315 20.7.24 Dec 07, 2009: BD Receives FDA Approval For BD ProbeTec Chlamydia Trachomatis Qx And BD ProbeTec Neisseria Gonorrhoeae QX Amplified DNA Assays ............................................................................... 315 20.7.25 Oct 06, 2009: BD Diagnostics Receives FDA 510(K) Approval For BD Vacutainer Rapid Serum Tube 316 20.7.26 Aug 04, 2009: BD Biosciences Announces The Launch Of BD FACSLink LIS For Labs Using BD Flow Cytometers......................................................................................................................................................... 316 20.7.27 Jul 29, 2009: BD Launches The New BD Nexiva Closed IV Catheter System In UK ........................ 317 20.7.28 Mar 23, 2009: FDA Grants 510(k) Clearance To BD ProbeTec Qx Amplified Assays For The Detection Of Chlamydia And Neisseria .................................................................................................................... 317 20.7.29 Mar 17, 2009: BD Announces The Launch Of BD OcuSeal Liquid Ocular Bandage ......................... 318 20.7.30 Mar 17, 2009: HyperBranch Medical Technology Announces The Licensing Of OcuSeal Liquid Ocular Bandage To BD .............................................................................................................................................. 318 20.7.31 Feb 26, 2009: First Approved Intradermal Influenza Vaccine In The European Union Uses BD Soluvia Microinjection System From BD .................................................................................................................. 318 20.7.32 Feb 10, 2009: BD Receives CE Mark For BD ProbeTec Qx Amplified Assays .................................. 319 20.7.33 Jan 14, 2009: BD Diagnostics Launches BD BACTEC FX Blood Culture System With The BD EpiCenter Operating System Worldwide .................................................................................................................. 319 20.7.34 Jan 12, 2009: BD Diagnostics Receives FDA 510(k) Clearance For Novel Molecular Assay to Diagnose Clostridium Difficile Infections .................................................................................................................. 320 20.7.35 Jan 12, 2009: BD Receives FDA 510(k) Clearance For BD GeneOhm Cdiff Molecular Assay To Diagnose Clostridium difficile Infections ................................................................................................................... 321 20.7.36 Dec 15, 2008: BD Biosciences Launches BD Human Pluripotent Stem Cell Sorting And Analysis Kit 321 20.7.37 Dec 04, 2008: BD Receives FDA Approval For The BD FocalPoint GS Imaging System To Enhance The Detection Of Cervical Cancer ............................................................................................................................ 322 20.7.38 Dec 01, 2008: BD Launches 8mm BD AutoShield Pen Needle ........................................................... 322 20.7.39 Nov 20, 2008: BD Announces Health Canada Licensing Of Novel Molecular Assay For Detection Of Clostridium difficile Toxin B Gene ............................................................................................................................. 323 20.7.40 Nov 08, 2008: BD Launches BD Atomic Edge Safety LRI Knives ....................................................... 323 20.7.41 Jul 07, 2008: BD Diagnostics Announces CE Marking Of A New Molecular Test To Diagnose Patients With Clostridium Difficile Infections ............................................................................................................ 324 20.7.42 Jul 07, 2008: BD Diagnostics Reports Submission Of GeneOhm Cdiff Assay For FDA Approval ... 324 20.7.43 Jun 02, 2008: New BD BACTEC FX Blood Culture Instrument With The BD EpiCenter Operating System Can Facilitate Fast And Effective Clinical Decisions For Patients With Bacterial Infections................... 325 20.7.44 May 23, 2008: BD Biosciences Announces The Launch Of BD AttoVision Software v1.6 ................ 325 20.7.45 May 01, 2008: BD Diagnostic Systems Announces CE Marking Of The BD GeneOhm VanR Molecular Test For The Rapid Detection Of Vancomycin Resistance ................................................................... 326 20.7.46 Mar 26, 2008: BD Medical’s BD Venflon Pro Safety IV Catheter Receives Award In Prestigious International Design Competition .............................................................................................................................. 326 20.7.47 Mar 26, 2008: BD Venflon Pro Safety Catheter Wins Award In Prestigious International Design Competition ................................................................................................................................................................. 327

Table of Contents



20.7.48 Feb 13, 2008: First European Application Filed For Product Using Innovative Intradermal Microinjection System BD Soluvia ............................................................................................................................ 327 20.7.49 Jan 02, 2008: BD Announces FDA 510(k) Clearance Of Two-Hour Test To Identify Superbug In Patients With Positive Blood Cultures ...................................................................................................................... 327 20.7.50 Jan 02, 2008: HyperBranch Receives CE Mark For OcuSeal ............................................................. 328 20.7.51 Dec 20, 2007: BD Launches GeneOhm StaphSR Assay In Europe ................................................... 328 20.7.52 Sep 08, 2007: Becton, Dickinson And Company Announces Launch Of New BD Atomic Edge Safety Knives 328 20.7.53 Aug 20, 2007: BD Announces Availability Of Ultra-Fine III Mini Pen Needle 5's Pouch Pack In India 329 20.7.54 Jun 29, 2007: BD Biosciences Introduces BD FACSDiva 6.0 Software ............................................ 329 20.7.55 May 22, 2007: BD Diagnostics Showcases BD Phoenix AP Instrument At General Meeting Of American Society For Microbiology .......................................................................................................................... 329 20.7.56 May 21, 2007: BD Announces CE Mark Approval For BD GeneOhm StaphSR Assay ..................... 330 20.7.57 May 03, 2007: BD Medical Announces The Launch Of BD Venflon Pro Safety IV Catheter ............ 330 20.7.58 Apr 26, 2007: Ability Of The BD ProbeTec ET System To Detect Variant Chlamydia trachomatis Is Confirmed 331 20.7.59 Apr 25, 2007: BD Submits BD GeneOhm StaphSR Assay For 510(K) Approval ............................... 331 20.7.60 Mar 28, 2007: BD Medical Announces The Launch Of The BD AutoShield Pen Needle .................. 332

20.8 Product Approvals............................................................................................................................................ 332 20.8.1 Apr 09, 2013: BD Receives FDA Approval For Max Cdiff Assay ............................................................ 332 20.8.2 Oct 11, 2012: BD Veritor System For Rapid Detection Of RSV Receives FDA 510(k) Clearance For Nasopharyngeal Wash, Aspirate And Swab In Transport Media Specimens ........................................................ 333 20.8.3 Oct 03, 2012: BD Diagnostics Receives 510(k) FDA Clearance For Nasopharyngeal Wash, Aspirate And Swab In Transport Media Specimens On BD Veritor System For Rapid Detection Of RSV ........................ 333 20.8.4 Sep 24, 2012: BD Diagnostics Receives FDA 510(k) Clearance For Nasopharyngeal Wash, Aspirate And Swab In Transport Media Specimens On BD Veritor System For Rapid Detection Of Flu A + B ................ 334 20.8.5 Feb 08, 2012: Alverix’s Partner BD Receives Japanese Regulatory Approval For BD Veritor System For Flu A+B ................................................................................................................................................................. 334 20.8.6 Dec 20, 2011: Alverix Partner BD Receives 510(k) Clearance And CLIA Waiver For BD Veritor System For Rapid Detection Of Flu A+B ................................................................................................................................ 335 20.8.7 Nov 24, 2011: BD Diagnostics Receives CE Mark For BD MAX MRSA Assay ..................................... 335 20.8.8 Jun 02, 2010: BD Diagnostics Receives FDA 510(k) Approval For BD MAX GBS Assay For Group B Streptococcus ............................................................................................................................................................. 336 20.8.9 Dec 07, 2009: BD Receives FDA Approval For BD ProbeTec Chlamydia Trachomatis Qx And BD ProbeTec Neisseria Gonorrhoeae QX Amplified DNA Assays ............................................................................... 336 20.8.10 Dec 07, 2009: BD Receives FDA Approval For BD ProbeTec Chlamydia Trachomatis Qx And BD ProbeTec Neisseria Gonorrhoeae QX Amplified DNA Assays ............................................................................... 337 20.8.11 Oct 06, 2009: BD Diagnostics Receives FDA 510(K) Approval For BD Vacutainer Rapid Serum Tube 337 20.8.12 Mar 23, 2009: FDA Grants 510(k) Clearance To BD ProbeTec Qx Amplified Assays For The Detection Of Chlamydia And Neisseria .................................................................................................................... 338

Table of Contents



20.8.13 Mar 23, 2009: FDA Grants 510(k) Clearance To BD ProbeTec Qx Amplified Assays For The Detection Of Chlamydia And Neisseria .................................................................................................................... 338 20.8.14 Feb 10, 2009: BD Receives CE Mark For BD ProbeTec Qx Amplified Assays .................................. 339 20.8.15 Feb 10, 2009: BD Receives CE Mark For BD ProbeTec Qx Amplified Assays .................................. 339 20.8.16 Jan 12, 2009: BD Diagnostics Receives FDA 510(k) Clearance For Novel Molecular Assay to Diagnose Clostridium Difficile Infections .................................................................................................................. 340 20.8.17 Jan 12, 2009: BD Receives FDA 510(k) Clearance For BD GeneOhm Cdiff Molecular Assay To Diagnose Clostridium difficile Infections ................................................................................................................... 340 20.8.18 Dec 04, 2008: BD Receives FDA Approval For The BD FocalPoint GS Imaging System To Enhance The Detection Of Cervical Cancer ............................................................................................................................ 341 20.8.19 Nov 20, 2008: BD Announces Health Canada Licensing Of Novel Molecular Assay For Detection Of Clostridium difficile Toxin B Gene ............................................................................................................................. 341 20.8.20 Jul 07, 2008: BD Diagnostics Announces CE Marking Of A New Molecular Test To Diagnose Patients With Clostridium Difficile Infections ............................................................................................................ 342 20.8.21 May 01, 2008: BD Diagnostic Systems Announces CE Marking Of The BD GeneOhm VanR Molecular Test For The Rapid Detection Of Vancomycin Resistance ................................................................... 343 20.8.22 Jan 02, 2008: BD Announces FDA 510(k) Clearance Of Two-Hour Test To Identify Superbug In Patients With Positive Blood Cultures ...................................................................................................................... 343 20.8.23 Jan 02, 2008: HyperBranch Receives CE Mark For OcuSeal ............................................................. 343 20.8.24 May 21, 2007: BD Announces CE Mark Approval For BD GeneOhm StaphSR Assay ..................... 344

20.9 Other Significant Developments .................................................................................................................... 344 20.9.1 Feb 27, 2013: Premier Awards New Contracts For Regional Anesthesia Trays .................................... 344 20.9.2 Oct 03, 2012: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Blood/Specimen Collection And Ancillary Products................................................................................................. 344 20.9.3 Oct 01, 2012: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Safety Phlebotomy ................................................................................................................................................................. 345 20.9.4 May 02, 2012: BD Signs ERS Engagement With HCL Technologies ..................................................... 345 20.9.5 Apr 17, 2012: Montefiore Medical Center To Launch System Wide Sharps Recycling Program ......... 345 20.9.6 Jan 24, 2012: Hospitals, Healthcare Providers To Benefit From New Premier Agreement For Blunt Cannula Access Devices ........................................................................................................................................... 346 20.9.7 Jan 20, 2011: Several Customers Select Bloom Energy's Bloom Electrons Service ............................ 346 20.9.8 Dec 06, 2010: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Automated Blood Culture And Mycobacterial Recovery Analyzers, Reagents, Consumables And Service ....... 347 20.9.9 Nov 15, 2010: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Safety IV Catheters ................................................................................................................................................................ 347 20.9.10 Nov 12, 2010: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Standard Hypodermic Products ................................................................................................................................ 347 20.9.11 Nov 04, 2010: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Safety Hypodermic Products ................................................................................................................................................. 348 20.9.12 Oct 06, 2010: Premier Announces New Agreements For Surgical Blades ......................................... 348 20.9.13 Sep 29, 2010: BD And Bruker Collaborate To Improve Microbial Identification And Antimicrobial Susceptibility Testing ................................................................................................................................................. 348 20.9.14 Aug 24, 2010: Becton Dickinson Spends $100,000 On Lobbying Efforts In Q2 2010 ....................... 349

Table of Contents



20.9.15 Aug 18, 2010: Texas Invests $1.56 Million In BD ................................................................................. 349 20.9.16 Jul 19, 2010: BD To Invest $38.4 Million To Build Warehouse And East Coast Distribution Center In Johnston County......................................................................................................................................................... 349 20.9.17 Mar 15, 2010: BD To Present At Barclays Capital 2010 Healthcare Conference .............................. 350 20.9.18 Jan 27, 2010: BD Increases Haiti Relief Fund To Include $5 Million In Product Donations .............. 350 20.9.19 Jan 15, 2010: BD Donates Up To $500,000 Of Medical Equipment For Haiti Earthquake Relief Efforts 350 20.9.20 Dec 31, 2009: Premier Awards New Contracts For Regional Anesthesia Trays And Related Products To Arrow International, BD And Smiths Medical ...................................................................................................... 351 20.9.21 Sep 03, 2009: BD Announces Flu Product Order From US Government ........................................... 351 20.9.22 May 08, 2009: BD Biosciences Announces Winners Of Annual Research Grant Program .............. 351 20.9.23 Mar 11, 2009: BD Biosciences Facility In San Jose, California Achieves LEED Silver Certification 352 20.9.24 Dec 01, 2008: BD Spends $0.08 Million On Lobbying In 3Q 2008 ...................................................... 353 20.9.25 Sep 10, 2008: BD Spends $0.14 Million On Lobbying In 2Q 2008 ...................................................... 353 20.9.26 Jun 10, 2008: 3-D Matrix Signs Contract With BD To Supply Peptide Hydrogel Products Worldwide For Research Use ...................................................................................................................................................... 353

21 Appendix ...................................................................................................................... 354

21.1 Research Methodology .................................................................................................................................... 355

21.2 Secondary Research ........................................................................................................................................ 355

21.3 Primary Research ............................................................................................................................................. 355

21.4 Models ................................................................................................................................................................ 356

21.5 Forecasts............................................................................................................................................................ 356

21.6 Expert Panels .................................................................................................................................................... 356

21.7 GlobalData Consulting ..................................................................................................................................... 356

21.8 Disclaimer .......................................................................................................................................................... 358

Table of Contents



1.1 List of Tables Table 1: Becton, Dickinson and Company, Key Facts, 2011 25

Table 2: Becton, Dickinson and Company, SWOT Analysis, 2011 48

Table 3: In Vitro Diagnostics (Histology And Cytology), Global, Company Share by Revenue ($m), 2011 57

Table 4: Becton, Dickinson and Company, In Vitro Diagnostics (Histology And Cytology), by Region, Revenue ($m) and Company Share (%), 2011 58

Table 5: Becton, Dickinson and Company, In Vitro Diagnostics (Histology And Cytology), by Country, Revenue ($m) and Company Share (%), 2011 60

Table 6: In Vitro Diagnostics (Infectious Immunology), Global, Company Share by Revenue ($m), 2011 62

Table 7: Becton, Dickinson and Company, In Vitro Diagnostics (Infectious Immunology), by Region, Revenue ($m) and Company Share (%), 2011 64

Table 8: Becton, Dickinson and Company, In Vitro Diagnostics (Infectious Immunology), by Country, Revenue ($m) and Company Share (%), 2011 66

Table 9: In Vitro Diagnostics (Microbiology Culture), Global, Company Share by Revenue ($m), 2011 68

Table 10: Becton, Dickinson and Company, In Vitro Diagnostics (Microbiology Culture), by Region, Revenue ($m) and Company Share (%), 2011 69

Table 11: Becton, Dickinson and Company, In Vitro Diagnostics (Microbiology Culture), by Country, Revenue ($m) and Company Share (%), 2011 71

Table 12: Hospital Supplies (Disposable Hospital Supplies), Global, Company Share by Revenue ($m), 2011 73

Table 13: Becton, Dickinson and Company, Hospital Supplies (Disposable Hospital Supplies), by Region, Revenue ($m) and Company Share (%), 2011 74

Table 14: Becton, Dickinson and Company, Hospital Supplies (Disposable Hospital Supplies), by Country, Revenue ($m) and Company Share (%), 2011 76

Table 15: Hospital Supplies (Syringes and Needles), Global, Company Share by Revenue ($m), 2011 78

Table 16: Becton, Dickinson and Company, Hospital Supplies (Syringes and Needles), by Region, Revenue ($m) and Company Share (%), 2011 80

Table 17: Becton, Dickinson and Company, Hospital Supplies (Syringes and Needles), by Country, Revenue ($m) and Company Share (%), 2011 82

Table 18: Drug Delivery Devices (Central Venous Catheters), Global, Company Share by Revenue ($m), 2011 84

Table 19: Becton, Dickinson and Company, Drug Delivery Devices (Central Venous Catheters), by Region, Revenue ($m) and Company Share (%), 2011 85

Table 20: Becton, Dickinson and Company, Drug Delivery Devices (Central Venous Catheters), by Country, Revenue ($m) and Company Share (%), 2011 87

Table 21: Diabetes Care Devices (Insulin Delivery), Global, Company Share by Revenue ($m), 2011 89

Table 22: Becton, Dickinson and Company, Diabetes Care Devices (Insulin Delivery), by Region, Revenue ($m) and Company Share (%), 2011 90

Table 23: Becton, Dickinson and Company, Diabetes Care Devices (Insulin Delivery), by Country, Revenue ($m) and Company Share (%), 2011 92

Table 24: Anesthesia and Respiratory Devices (Regional Anesthesia Disposables), Global, Company Share by Revenue ($m), 2011 94

Table 25: Becton, Dickinson and Company, Anesthesia and Respiratory Devices (Regional Anesthesia Disposables), by Region, Revenue ($m) and Company Share (%), 2011 96

Table 26: Becton, Dickinson and Company, Anesthesia and Respiratory Devices (Regional Anesthesia Disposables), by Country, Revenue ($m) and Company Share (%), 2011 98

Table 27: Becton, Dickinson and Company, Medical Equipment, Global, Revenue ($m) and Company Share (%) by Category, 2011 101

Table of Contents



Table 28: Becton, Dickinson and Company, Medical Equipment, Asia-Pacific, Revenue ($m) and Company Share (%) by Category, 2011 104

Table 29: Becton, Dickinson and Company, Medical Equipment, Australia, Revenue ($m) and Company Share (%) by Category, 2011 107

Table 30: Becton, Dickinson and Company, Medical Equipment, China, Revenue ($m) and Company Share (%) by Category, 2011 110

Table 31: Becton, Dickinson and Company, Medical Equipment, India, Revenue ($m) and Company Share (%) by Category, 2011 113

Table 32: Becton, Dickinson and Company, Medical Equipment, Japan, Revenue ($m) and Company Share (%) by Category, 2011 116

Table 33: Becton, Dickinson and Company, Medical Equipment, Other Asia-Pacific, Revenue ($m) and Company Share (%) by Category, 2011 119

Table 34: Becton, Dickinson and Company, Medical Equipment, Europe, Revenue ($m) and Company Share (%) by Category, 2011 122

Table 35: Becton, Dickinson and Company, Medical Equipment, France, Revenue ($m) and Company Share (%) by Category, 2011 125

Table 36: Becton, Dickinson and Company, Medical Equipment, Germany, Revenue ($m) and Company Share (%) by Category, 2011 128

Table 37: Becton, Dickinson and Company, Medical Equipment, Italy, Revenue ($m) and Company Share (%) by Category, 2011 131

Table 38: Becton, Dickinson and Company, Medical Equipment, Spain, Revenue ($m) and Company Share (%) by Category, 2011 134

Table 39: Becton, Dickinson and Company, Medical Equipment, United Kingdom, Revenue ($m) and Company Share (%) by Category, 2011 137

Table 40: Becton, Dickinson and Company, Medical Equipment, Other Europe, Revenue ($m) and Company Share (%) by Category, 2011 140

Table 41: Becton, Dickinson and Company, Medical Equipment, Middle East and Africa, Revenue ($m) and Company Share (%) by Category, 2011 143

Table 42: Becton, Dickinson and Company, Medical Equipment, North America, Revenue ($m) and Company Share (%) by Category, 2011 146

Table 43: Becton, Dickinson and Company, Medical Equipment, Canada, Revenue ($m) and Company Share (%) by Category, 2011 149

Table 44: Becton, Dickinson and Company, Medical Equipment, United States, Revenue ($m) and Company Share (%) by Category, 2011 152

Table 45: Becton, Dickinson and Company, Medical Equipment, South and Central America, Revenue ($m) and Company Share (%) by Category, 2011 155

Table 46: Becton, Dickinson and Company, Medical Equipment, Brazil, Revenue ($m) and Company Share (%) by Category, 2011 158

Table 47: Becton, Dickinson and Company, Medical Equipment, Other South and Central America, Revenue ($m) and Company Share (%) by Category, 2011 161

Table 48: Becton, Dickinson and Company, Share Holding Structure 162

Table 49: Becton, Dickinson and Company, Key Employees 163

Table 50: Becton, Dickinson and Company, Other Locations 167

Table 51: Becton, Dickinson and Company, Subsidiaries 168

Table 52: Becton, Dickinson and Company, Deals Volume Summary, 2007 to 2012 172

Table 53: Becton, Dickinson and Company, Deals Summary By Region, 2007 to 2012 173

Table 54: Becton, Dickinson and Company, Deals Summary, 2007 to 2012 174

Table 55: BD Diagnostics Completes Acquisition Of Lab Systems Division From Dynacon 175

Table of Contents



Table 56: Sirigen Secures $3 Million In Venture Financing 176

Table 57: Sirigen Secures $6.13 Million In Venture Financing 178

Table 58: Accuri Cytometers Secures $6 Million In Series E Preferred Stock Financing Round 180

Table 59: Accuri Cytometers Secures $4 Million In Series D Round Of Financing 182

Table 60: Sirigen Secures Additional $1.96 Million In Financing 184

Table 61: Pathogenetix Secures $4.5 Million In Venture Financing 186

Table 62: Accuri Cytometers Secures $13 Million In Series C Financing 187

Table 63: Sirigen Secures $3.96 Million In Financing 189

Table 64: Accuri Cytometers Raises $5 Million In Series B Financing 190

Table 65: Becton, Dickinson and Company Completes Sale Of Ophthalmic Systems Unit To RoundTable Healthcare Partners 191

Table 66: Asuragen Enters Into Licensing Agreement With Becton, Dickinson 193

Table 67: SDIX Enters Into Licensing Agreement With BD Diagnostic 194

Table 68: Acacia Research Enters Into Licensing Agreement With Becton, Dickinson And Argon Medical 195

Table 69: Becton, Dickinson Enters Into Licensing Agreement With Advanced Analytical Technologies For Micro PRO Microbial Detection System 196

Table 70: UCL Business Enters Into Licensing Agreement With Becton, Dickinson 197

Table 71: Exiqon Enters Into Licensing Agreement With Becton, Dickinson 198

Table 72: Caliper Life Sciences Enters Into Licensing Agreement With Becton, Dickinson and Company 199

Table 73: Arbor Vita Signs An Agreement With Becton, Dickinson and Company 200

Table 74: Ivera Medical Enters Into An Agreement With Becton, Dickinson and Company 201

Table 75: Proteome Systems Enters Into Licensing Agreement With Becton, Dickinson and Company 202

Table 76: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 203

Table 77: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 204

Table 78: Juvenile Diabetes Research Foundation Extends Co-Development Agreement With Becton, Dickinson 205

Table 79: BD Diagnostics Enters Into Co-Development Agreement With Biodiversity 206

Table 80: BD Diagnostics Enters Into Co-Development Agreement With Lab21 207

Table 81: BD Diagnostic Enters Into Co-Development Agreement With Diagenode 208

Table 82: BD Diagnostic Enters Into An Agreement With Bruker Daltonics 209

Table 83: Alverix Enters Into Co-Development Agreement With Becton, Dickinson 210

Table 84: JDRF Enters Into An Agreement With Becton, Dickinson and Company 211

Table 85: BD Diagnostics Enters Into An Agreement With HandyLab 212

Table 86: Becton, Dickinson and Company Signs An Agreement With Fujirebio Diagnostics 213

Table 87: LiDCO Group Extends Co-Marketing Agreement With Becton, Dickinson and Company 214

Table 88: LiDCO Group Enters Into Distribution Agreement With Becton, Dickinson and Company 215

Table 89: HyperBranch Medical Technology Enters Into An Agreement With BD 216

Table 90: Luminex Enters Into An Agreement With BD Diagnostics-TriPath 217

Table 91: U.S. Genomics Enters Into Co-Development Agreement With Becton, Dickinson and Company 218

Table 92: Accelr8 Technology Enters Into Co-Development Agreement With Becton, Dickinson and Company 219

Table 93: Proteome Systems Enters Into Agreement With Becton, Dickinson 220

Table 94: BD Diagnostic Systems Enters Into Licensing Agreement With Lonza Group 221

Table of Contents



Table 95: Centenary Institute of Cancer Medicine and Cell Biology And Bio-Link Enter Into Licensing Agreement With Becton, Dickinson and Company 222

Table 96: Becton, Dickinson Files Registration Statement For Public Offering Of Securities 223

Table 97: Becton, Dickinson Completes Public Offering Of Notes Due 2021 For $1 Billion 224

Table 98: Becton, Dickinson Completes Public Offering Of Notes Due 2016 For $500 Million 225

Table 99: Becton, Dickinson and Company Completes Underwritten Public Offering Of Senior Unsecured Notes Due 2040 For $300 Million 226

Table 100: Becton, Dickinson Completes Underwritten Public Offering Of Senior Unsecured Notes Due 2020 For $700 Million 227

Table 101: Becton, Dickinson and Company Completes Public Offering Of 6% Notes For $250 Million 228

Table 102: Becton, Dickinson and Company Completes Public Offering Of 5% Notes For $500 Million 230

Table 103: Corning Completes Acquisition of Majority Stake In Discovery Labware Unit Of Becton, Dickinson For $730 Million 232

Table 104: Becton, Dickinson and Company Completes Sale Of Assets To Argon Medical Devices 234

Table 105: Becton, Dickinson and Company Completes Sale Of Assets To Aspen Surgical Products 235

Table 106: 3M Acquires ACE Branded Bandage And Thermometer Product Line From BD 236

Table 107: Becton, Dickinson Acquires Cato Software Solutions, Maker Of Medical Software Solutions 237

Table 108: Becton, Dickinson Completes Acquisition Of Safety Syringes, Developer Of Anti-Needlestick Devices 238

Table 109: Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes 239

Table 110: Becton, Dickinson Acquires KIESTRA, Provider Of Lab Automation Solutions 241

Table 111: Becton, Dickinson Completes Acquisition Of Carmel Pharma 242

Table 112: Becton, Dickinson Completes Acquisition Of Accuri Cytometers 244

Table 113: Becton, Dickinson and Company Completes Acquisition Of HandyLab 246

Table 114: Priveq Acquires 25.9% Stake In Carmel Pharma From 3i 247

Table 115: USD to Local Currency, Average Exchange Rate, 2011 357

1.2 List of Figures Figure 1: In Vitro Diagnostics (Histology And Cytology), Global, Company Share (%), 2011 ................................................... 56

Figure 2: Becton, Dickinson and Company, In Vitro Diagnostics (Histology And Cytology), by Region, Company Share (%) , 2011 .............................................................................................................................................................................................. 58

Figure 3: Becton, Dickinson and Company, In Vitro Diagnostics (Histology And Cytology), by Country, Company Share (%) , 2011 .............................................................................................................................................................................................. 59

Figure 4: In Vitro Diagnostics (Infectious Immunology), Global, Company Share (%), 2011 ..................................................... 61

Figure 5: Becton, Dickinson and Company, In Vitro Diagnostics (Infectious Immunology), by Region, Company Share (%), 2011 .............................................................................................................................................................................................. 63

Figure 6: Becton, Dickinson and Company, In Vitro Diagnostics (Infectious Immunology), by Country, Company Share (%), 2011 .............................................................................................................................................................................................. 65

Figure 7: In Vitro Diagnostics (Microbiology Culture), Global, Company Share (%), 2011 ........................................................ 67

Figure 8: Becton, Dickinson and Company, In Vitro Diagnostics (Microbiology Culture), by Region, Company Share (%), 2011 .............................................................................................................................................................................................. 69

Figure 9: Becton, Dickinson and Company, In Vitro Diagnostics (Microbiology Culture), by Country, Company Share (%), 2011 .............................................................................................................................................................................................. 70

Figure 10: Hospital Supplies (Disposable Hospital Supplies), Global, Company Share (%), 2011 ........................................... 72

Table of Contents



Figure 11: Becton, Dickinson and Company, Hospital Supplies (Disposable Hospital Supplies), by Region, Company Share (%), 2011 ...................................................................................................................................................................................... 74

Figure 12: Becton, Dickinson and Company, Hospital Supplies (Disposable Hospital Supplies), by Country, Company Share (%), 2011 ...................................................................................................................................................................................... 75

Figure 13: Hospital Supplies (Syringes and Needles), Global, Company Share (%), 2011 ....................................................... 77

Figure 14: Becton, Dickinson and Company, Hospital Supplies (Syringes and Needles), by Region, Company Share (%), 2011 .............................................................................................................................................................................................. 79

Figure 15: Becton, Dickinson and Company, Hospital Supplies (Syringes and Needles), by Country, Company Share (%), 2011 .............................................................................................................................................................................................. 81

Figure 16: Drug Delivery Devices (Central Venous Catheters), Global, Company Share (%), 2011 ........................................ 83

Figure 17: Becton, Dickinson and Company, Drug Delivery Devices (Central Venous Catheters), by Region, Company Share (%), 2011 ........................................................................................................................................................................... 85

Figure 18: Becton, Dickinson and Company, Drug Delivery Devices (Central Venous Catheters), by Country, Company Share (%), 2011 ........................................................................................................................................................................... 86

Figure 19: Diabetes Care Devices (Insulin Delivery), Global, Company Share (%), 2011 ......................................................... 88

Figure 20: Becton, Dickinson and Company, Diabetes Care Devices (Insulin Delivery), by Region, Company Share (%), 2011 .............................................................................................................................................................................................. 90

Figure 21: Becton, Dickinson and Company, Diabetes Care Devices (Insulin Delivery), by Country, Company Share (%), 2011 .............................................................................................................................................................................................. 91

Figure 22: Anesthesia and Respiratory Devices (Regional Anesthesia Disposables), Global, Company Share (%), 2011 .... 93

Figure 23: Becton, Dickinson and Company, Anesthesia and Respiratory Devices (Regional Anesthesia Disposables), by Region, Company Share (%), 2011 ............................................................................................................................................ 95

Figure 24: Becton, Dickinson and Company, Anesthesia and Respiratory Devices (Regional Anesthesia Disposables), by Country, Company Share (%), 2011........................................................................................................................................... 97

Figure 25: Becton, Dickinson and Company, Medical Equipment, Global, Category Revenue Share (%), 2011 .................... 99

Figure 26: Becton, Dickinson and Company, Medical Equipment, Global, Company Share (%) by Category, 2011 ............ 100

Figure 27: Becton, Dickinson and Company, Medical Equipment, Asia-Pacific, Category Revenue Share (%), 2011 .......... 102

Figure 28: Becton, Dickinson and Company, Medical Equipment, Asia-Pacific, Company Share (%) by Category, 2011 .... 103

Figure 29: Becton, Dickinson and Company, Medical Equipment, Australia, Category Revenue Share (%), 2011 ............... 105

Figure 30: Becton, Dickinson and Company, Medical Equipment, Australia, Company Share (%) by Category, 2011 ......... 106

Figure 31: Becton, Dickinson and Company, Medical Equipment, China, Category Revenue Share (%), 2011 ................... 108

Figure 32: Becton, Dickinson and Company, Medical Equipment, China, Company Share (%) by Category, 2011 ............. 109

Figure 33: Becton, Dickinson and Company, Medical Equipment, India, Category Revenue Share (%), 2011 ..................... 111

Figure 34: Becton, Dickinson and Company, Medical Equipment, India, Company Share (%) by Category, 2011 ............... 112

Figure 35: Becton, Dickinson and Company, Medical Equipment, Japan, Category Revenue Share (%), 2011 ................... 114

Figure 36: Becton, Dickinson and Company, Medical Equipment, Japan, Company Share (%) by Category, 2011 ............. 115

Figure 37: Becton, Dickinson and Company, Medical Equipment, Other Asia-Pacific, Category Revenue Share (%), 2011 117

Figure 38: Becton, Dickinson and Company, Medical Equipment, Other Asia-Pacific, Company Share (%) by Category, 2011 ............................................................................................................................................................................................ 118

Figure 39: Becton, Dickinson and Company, Medical Equipment, Europe, Category Revenue Share (%), 2011 ................. 120

Figure 40: Becton, Dickinson and Company, Medical Equipment, Europe, Company Share (%) by Category, 2011 ........... 121

Figure 41: Becton, Dickinson and Company, Medical Equipment, France, Category Revenue Share (%), 2011.................. 123

Figure 42: Becton, Dickinson and Company, Medical Equipment, France, Company Share (%) by Category, 2011............ 124

Figure 43: Becton, Dickinson and Company, Medical Equipment, Germany, Category Revenue Share (%), 2011 .............. 126

Table of Contents



Figure 44: Becton, Dickinson and Company, Medical Equipment, Germany, Company Share (%) by Category, 2011 ........ 127

Figure 45: Becton, Dickinson and Company, Medical Equipment, Italy, Category Revenue Share (%), 2011 ...................... 129

Figure 46: Becton, Dickinson and Company, Medical Equipment, Italy, Company Share (%) by Category, 2011 ................ 130

Figure 47: Becton, Dickinson and Company, Medical Equipment, Spain, Category Revenue Share (%), 2011 .................... 132

Figure 48: Becton, Dickinson and Company, Medical Equipment, Spain, Company Share (%) by Category, 2011 .............. 133

Figure 49: Becton, Dickinson and Company, Medical Equipment, United Kingdom, Category Revenue Share (%), 2011... 135

Figure 50: Becton, Dickinson and Company, Medical Equipment, United Kingdom, Company Share (%) by Category, 2011 .................................................................................................................................................................................................... 136

Figure 51: Becton, Dickinson and Company, Medical Equipment, Other Europe, Category Revenue Share (%), 2011 ....... 138

Figure 52: Becton, Dickinson and Company, Medical Equipment, Other Europe, Company Share (%) by Category, 2011 . 139

Figure 53: Becton, Dickinson and Company, Medical Equipment, Middle East and Africa, Category Revenue Share (%), 2011 ............................................................................................................................................................................................ 141

Figure 54: Becton, Dickinson and Company, Medical Equipment, Middle East and Africa, Company Share (%) by Category, 2011 ............................................................................................................................................................................................ 142

Figure 55: Becton, Dickinson and Company, Medical Equipment, North America, Category Revenue Share (%), 2011 ..... 144

Figure 56: Becton, Dickinson and Company, Medical Equipment, North America, Company Share (%) by Category, 2011 145

Figure 57: Becton, Dickinson and Company, Medical Equipment, Canada, Category Revenue Share (%), 2011 ................ 147

Figure 58: Becton, Dickinson and Company, Medical Equipment, Canada, Company Share (%) by Category, 2011 .......... 148

Figure 59: Becton, Dickinson and Company, Medical Equipment, United States, Category Revenue Share (%), 2011 ....... 150

Figure 60: Becton, Dickinson and Company, Medical Equipment, United States, Company Share (%) by Category, 2011 . 151

Figure 61: Becton, Dickinson and Company, Medical Equipment, South and Central America, Category Revenue Share (%), 2011 ............................................................................................................................................................................................ 153

Figure 62: Becton, Dickinson and Company, Medical Equipment, South and Central America, Company Share (%) by Category, 2011........................................................................................................................................................................... 154

Figure 63: Becton, Dickinson and Company, Medical Equipment, Brazil, Category Revenue Share (%), 2011 .................... 156

Figure 64: Becton, Dickinson and Company, Medical Equipment, Brazil, Company Share (%) by Category, 2011 .............. 157

Figure 65: Becton, Dickinson and Company, Medical Equipment, Other South and Central America, Category Revenue Share (%), 2011 ......................................................................................................................................................................... 159

Figure 66: Becton, Dickinson and Company, Medical Equipment, Other South and Central America, Company Share (%) by Category, 2011........................................................................................................................................................................... 160

Figure 67: Becton, Dickinson and Company, Deals Volume Summary, 2007 to 2012............................................................. 172

Figure 68: Becton, Dickinson and Company, Deals Summary By Region, 2007 to 2012 ........................................................ 173

Becton, Dickinson and Company


© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form Page22

2 Introduction GlobalData Medical Equipment Company Reports are ideal guide for anyone wishing to understand the market better in terms of revenues and competitive landscape.

2.1 What Is This Report About?

This report is an essential source for data, analysis and strategic insights into the company. The report provides key information relating to company share analysis by market, category, region and country. The report examines company’s business structure and operations, history and products and provides an analysis of its key revenue lines.

Becton, Dickinson and Company



3 Definitions of Markets/Categories Covered

3.1 In Vitro Diagnostics In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. Such reagents, instruments and systems are intended for use in the collection, preparation and examination of specimens taken from the human body. The categories tracked under this market are clinical chemistry, immunochemistry, haematology, histology & cytology, infectious immunology, microbiology culture and genetic testing. In this market only values have been tracked.

3.1.1 Histology And Cytology

These are reagent test kits and instruments used in tissue and cell typing techniques. Flow cytometers, monoclonal antibodies and tissue typing reagents have been tracked under this category.

3.1.2 Infectious Immunology

This category includes reagents and test kits used for the detection or quantification of infectious agents like bacteria and viruses by using antigen-antibody (Ag – Ab) and nucleic acid tests.

3.1.3 Microbiology Culture

This category includes reagents used for the preparation of growth medium for microbial organisms. This category also includes dehydrated and prepared culture media for micro organism growth.

3.2 Hospital Supplies

The hospital supplies market includes devices and consumables that serve as adjunct in treatment, transportation, disinfection and preliminary diagnosis of patients in a hospital. This market includes sterilization and disinfectant equipment, syringes and needles, mobility aids and transportation, disposable hospital supplies, patient examination devices and operating room equipment. Catheters, needle free injections, bandages, sutures and staples are not covered in this market.

3.2.1 Disposable Hospital Supplies

Disposable hospital supplies are single use products that are destroyed after use. These include gloves, gowns, drapes and procedure kits and trays.

3.2.2 Syringes and Needles

Syringes are medical instruments used to inject a drug or extract body fluids. These are further classified as general and specialized syringes. It does not include needle free injections and insulin syringes.

3.3 Drug Delivery Devices

Drug delivery devices are used for administration of drug compounds in effective ways. They include both hospital and home care devices. Metered dose inhaler devices, central venous catheters, needle free injections and infusion systems are tracked under this market.



3.3.1 Central Venous Catheters

A central venous catheter is a long, thin, flexible tube used to administer medicines, fluids, nutrients, or blood products and to monitor haemodynamic status of the patients in surgical and critical care settings over a long period of time, usually several weeks or more. These come in different sizes. Antimicrobial & Non antimicrobial central venous catheters are included under this category.

3.4 Diabetes Care Devices Diabetes care devices are used in the treatment and management of diabetes. They include home and personal care use devices. Glucose monitoring devices and insulin delivery devices have been tracked under this market.

3.4.1 Insulin Delivery

Insulin delivery devices are used to inject measured doses of insulin through the skin and into the fatty tissue below. Insulin delivery devices included in this market are syringes, pens and insulin pumps. Non-percutaneous delivery devices such as inhaled, buccal and ocular are not included in this category.

3.5 Anesthesia and Respiratory Devices Anesthesia and respiratory devices include devices used in administering anesthesia during surgery, devices used in respiratory assistance and respiratory function measurement. The anesthesia and respiratory devices market covers airway and anesthesia devices, anesthesia machines, pain management devices, regional anesthesia disposables, respiratory devices, respiratory disposables, respiratory measurement devices and sleep apnea diagnostic systems. Value, distribution and company shares figures reflect annual gross sales of anesthesia and respiratory devices. Volume figures reflect the annual unit sales of anesthesia and respiratory devices. Average price denotes the average of the range of prices at which these devices are sold.

3.5.1 Regional Anesthesia Disposables

Regional Anesthesia Disposables consist of needles, catheters and trays used to perform various types of anesthesia procedures such as; epidural anesthesia, spinal anesthesia and peripheral anesthesia.



4 Company Snapshot

4.1 Key Facts

Table 1: Becton, Dickinson and Company, Key Facts, 2011

Web Address

Turnover (in USD Million)

Financial year-end

Number of Employees

NYSE Source: GlobalData Company Website

4.2 Company Overview Becton, Dickinson and Company (BD) is a medical technology company. It manufactures and sells medical devices, reagents and instrument systems used by life science researchers, healthcare institutions, clinical laboratories, pharmaceutical industry and general public. The company provides a broad range of products such as syringes, needles, blood collection devices, IV catheters and surgical instruments. The company through BD Technologies conducts research and development activities to improve manufacturing and process methods. Its products are manufactured and sold in the US, Canada, Europe, the Middle East, Africa, Japan, Asia Pacific and Latin America. BD is headquartered in New Jersey, the US. The company focuses on establishing its position in the marketplace through new product launches, network expansion, internal development, in-licensing of technology and products, acquisitions and strategic alliances

4.3 Financial Performance

4.4 SWOT Snapshot


© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form Page 56

10 Competitive Landscape

10.1 In Vitro Diagnostics (Histology And Cytology), Global, Company Share (%), 2011

Figure 1: In Vitro Diagnostics (Histology And Cytology), Global, Company Share (%), 2011

Note: Company Share estimates are based on company reports, secondary research and primary research Source: GlobalData



Table 3: In Vitro Diagnostics (Histology And Cytology), Global, Company Share by Revenue ($m), 2011

Company Name 2011

Source: GlobalData



10.2 Becton, Dickinson and Company, In Vitro Diagnostics (Histology And Cytology), by Region, Company Share (%) , 2011

Figure 2: Becton, Dickinson and Company, In Vitro Diagnostics (Histology And Cytology), by Region, Company Share (%) , 2011

Note: Company share estimates are based on company reports, secondary research and primary research Source: GlobalData

Table 4: Becton, Dickinson and Company, In Vitro Diagnostics (Histology And Cytology), by Region, Revenue ($m) and Company Share (%), 2011

Geography Company Revenue ($m) Company Share (%) Market Value ($m)

Note: Company share estimates are based on company reports, secondary research and primary research Source: GlobalData

Appendix



21 Appendix The data and analysis within this report is driven by Medical eTrack

Medical eTrack gives you the key information to drive sales, investment and deal making activity in your business. It includes the following information:

15,000+ Market size data tables across 740 medical equipment segments and 39 countries with historic data from 2004 forecast to 2018

6,000+ Primary expert interviews conducted per annum for ensuring data and report quality

1,100+ Conferences on medical equipment covered

1,000+ Industry leading reports per annum covering growing sectors, market trends, investment opportunities and competitive landscape

600+ Analysis reports covering market and pipeline product analysis reports by indication, medical equipment trends and issue reports and investment and M&A trend reports worth over $3 Million

43,000+ Medical equipment companies profiled

1,500+ Private, emerging and technology start-up company profiles

1,500+ Medical equipment manufacturers in China and India

1,500+ Medical equipment companies in Japan

700+ Companies with revenue splits and market shares by category

1,500+ Quarterly and annual medical equipment company financials

700+ Medical equipment company SWOT’s

9,000+ Pipeline product profiles

8,000+ Marketed product profiles

14,000+ Clinical trials

15,000+ Trial investigators

13,000+ New product patents

3,300+ Companies with products in development

17,000+ Deals in the medical equipment industry

1,100+ Surgical and diagnostic procedures by therapy area

40+ Key healthcare indicators by country

o For more information or to receive a free demo of the service visit

http://www.medicaletrack.com/contactus.aspx?RD=Demo=

Appendix



21.1 Research Methodology GlobalData’s dedicated research and analysis teams consists of qualified professionals with experience in marketing, market research, consulting background in the medical devices industry and advanced statistical expertise.

GlobalData adheres to the codes of practice of the Market Research Society (www.mrs.org.uk) and the Strategic and Competitive Intelligence Professionals (www.scip.org).

All GlobalData databases are continuously updated and revised. The following research methodology is followed for all databases and reports.

21.2 Secondary Research

The research process begins with exhaustive secondary research on internal and external sources being carried out to source qualitative and quantitative information relating to each market.

The secondary research sources that are typically referred to include, but are not limited to:

Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings;

Industry trade journals, scientific journals and other technical literature;

Internal and external proprietary databases;

Relevant patent and regulatory databases;

National government documents, statistical databases and market reports;

Procedure registries; and

News articles, press releases and web-casts specific to the companies operating in the market.

21.3 Primary Research

GlobalData conducts thousands of interviews a year with industry participants and commentators in order to validate its data and analysis. A typical research interview fulfills the following functions:

It provides first-hand information on market size, market trends, growth trends, competitive landscape and future outlook;

Helps in validating and strengthening the secondary research findings; and

Further develops the analysis team’s expertise and market understanding.

Primary research involves e-mail interactions and telephonic interviews for each market, category, segment and sub-segment across geographies.

The participants who typically take part in such a process include, but are not limited to:

Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers;

Hospital stores, laboratories, pharmacies, distributors and paramedics;

Outside experts: investment bankers, valuation experts, research analysts specializing in specific medical equipment markets; and

Appendix



Key opinion leaders: physicians and surgeons specializing in different therapeutic areas corresponding to different kinds of medical equipment.

21.4 Models

Where no hard data is available, GlobalData uses modeling and estimates in order to produce comprehensive data sets. The following rigorous methodology is adopted:

Available hard data is cross-referenced with the following data types to produce estimates:

Demographic data on population segments;

Macro-economic indicators such as GDP, inflation rate;

Healthcare indicators such as health expenditure, physician base, healthcare infrastructure and facilities; and

Selected epidemiological and procedure statistics.

21.5 Forecasts GlobalData uses proprietary forecast models. The following four factors are utilized in the forecast models:

Historic growth rates;

Macro-indicators such as population trends and healthcare spending;

Forecast epidemiological data; and

Qualitative trend information and assumptions.

The data is then cross-checked by the expert panel.

21.6 Expert Panels GlobalData uses a panel of experts to cross-verify its databases and forecasts.

GlobalData’s expert panel comprises marketing managers, product specialists, international sales managers from medical device companies; academics from research universities, KOLs from hospitals, consultants from venture capital funds and distributors/suppliers of medical equipment and supplies etc.

Historic data and forecasts are relayed to GlobalData’s expert panel for feedback and adjusted in accordance with their feedback.

21.7 GlobalData Consulting

We hope that the data and analysis in this brief will help you make informed and imaginative business decisions. If you have further requirements, GlobalData’s consulting team may be able to help you. GlobalData offers tailor-made analytical and advisory services to drive your key strategic decisions.

Appendix



Currency Conversion

Revenues are calculated in constant currency (USD) in the report.

Table 115: USD to Local Currency, Average Exchange Rate, 2011 Country Currency Code Conversion Factor United States USD 1.000 Canada CAD 0.989 Austria EUR 0.719 Belgium EUR 0.719 Czech Republic CZK 17.678 Denmark DKK 5.356 Finland EUR 0.719 France EUR 0.719 Germany EUR 0.719 Greece EUR 0.719 Hungary HUF 200.982 Ireland EUR 0.719 Italy EUR 0.719 Netherlands EUR 0.719 Norway NOK 5.606 Poland PLN 2.962 Portugal EUR 0.719 Russian Federation RUB 29.389 Spain EUR 0.719 Sweden SEK 6.491 Switzerland CHF 0.887 Turkey TRY 1.679 United Kingdom GBP 0.624 Australia AUD 0.969 China CNY 6.464 India INR 47.041 Japan JPY 79.722 New Zealand NZD 1.265 Republic of Korea KRW 1,107.542 Taiwan TWD 29.388 Argentina ARS 4.127 Brazil BRL 1.673 Chile CLP 483.417 Mexico MXN 12.432 Egypt EGP 5.944 Israel ILS 3.577 Saudi Arabia SAR 3.750 South Africa ZAR 7.251 United Arab Emirates AED 3.673 Source: GlobalData

Appendix



21.8 Disclaimer All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise without the prior permission of the publisher, GlobalData.

gdme0833cdb - becton, dickinson and company market share ... · becton, dickinson and company...

Documents